Home   /   Pressrelease    /   

Interim report January-March 2...

Interim report January-March 2021

First quarter 2021 (1 Jan – 31 Mar)
• Net sales amounted to SEK 58.3 million (46.5), corresponding to an increase of 26 percent in SEK and 38 percent in local currencies. Net sales of non-durable goods amounted to SEK 54.9 million (44.2), corresponding to an increase of 24 percent in SEK and 36 percent in local currencies.
• Machine perfusion constituted 53 percent (31) of net sales.
• Adjusted operating profit before depreciation and amortization (EBITDA) amounted to SEK 6.3 million (5.1), corresponding to an adjusted EBITDA margin of 11 percent (11). Reported EBITDA amounted to SEK 11.2 million (7.6), corresponding to an EBITDA margin of 19 percent (16).
• Adjusted operating profit (EBIT) amounted to SEK -1.8 million (-2.5). Reported EBIT amounted to SEK 3.2 million (0.0).
• Net profit amounted to SEK 6.0 million (6.5). Earnings per share amounted to SEK 0.21 (0.25).
Cash and cash equivalents at the end of the quarter amounted to SEK 350.3 million (158.7).

Significant events during the quarter
• An article published in the scientific journal The New England Journal of Medicine, shows that oxygenated perfusion of the donated liver before transplantation has a significant positive impact on the outcomes after transplantation.
• First patients transplanted in the Australian heart preservation study.

CEO comment
“The first quarter of the year was positive in several respects. Sales of machine perfusion in Thoracic totaled SEK 21 million, an increase of 45 percent year-on-year. In the US, the AOPO (the Association of Organ Procurement Organizations) presented a new groundbreaking target of increasing the number of transplants by 50 percent in the period until 2026, which creates important business opportunities for XVIVO. The main highlight in the first quarter was an article in the New England Journal of Medicine in February which emphasized the significant advantages of oxygenated perfusion of liver before transplantation.”

Invitation to conference call
CEO Dag Andersson and CFO Kristoffer Nordström will present the report in a conference call today at 2.00 p.m. CET.
Telephone US: +1 631 913 1422, Telephone UK: +44 333 300 0804. PIN: 16950415#

April 21, 2021

Dag Andersson

Fill out the form to watch the video